Brentuximab Vedotin Granted FDA Breakthrough Therapy Designation in Front-Line Advanced Hodgkin Lymphoma

October 9, 2017 – On October 2, Seattle Genetics, Inc, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to brentuximab vedotin in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin lymphoma. The positive topline results of the phase III ECHELON-1 clinical trial were announced in June 2017, and full data will be presented at the upcoming 2017 American Society of … (leggi tutto)